Great arit_老虎社区_美港股上老虎

octa8
2021-12-23

Great ariticle, would you like to share it?

Cocrystal Pharma shares surged more than 9% in premarket trading<blockquote>Cocrystal Pharma股价在盘前交易中飙升超过9%</blockquote>

Cocrystal Pharma shares surged more than 9% in premarket trading. Cocrystal Pharma, Inc. announces t

Cocrystal Pharma shares surged more than 9% in premarket trading<blockquote>Cocrystal Pharma股价在盘前交易中飙升超过9%</blockquote>

免责声明：上述内容仅代表发帖人个人观点，不构成本平台的任何投资建议。

推荐
最新

暂无评论

热议股票

{"i18n":{"language":"zh_CN"},"data":{"magic":2,"id":691279519,"tweetId":"691279519","gmtCreate":1640216359084,"gmtModify":1640216361693,"author":{"id":3563518698255751,"idStr":"3563518698255751","authorId":3563518698255751,"authorIdStr":"3563518698255751","name":"octa8","avatar":"https://static.tigerbbs.com/a9866d6e2ee91185e34a0a44121ba0f1","vip":1,"userType":1,"introduction":"","boolIsFan":false,"boolIsHead":false,"crmLevel":11,"crmLevelSwitch":0,"individualDisplayBadges":[],"fanSize":263,"starInvestorFlag":false},"themes":[],"images":[],"coverImages":[],"extraTitle":"","html":"<html><head></head><body>\nGreat ariticle, would you like to share it?</body></html>","htmlText":"<html><head></head><body>\nGreat ariticle, would you like to share it?</body></html>","text":"Great ariticle, would you like to share it?","highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"favoriteSize":0,"link":"https://laohu8.com/post/691279519","repostId":1162556937,"repostType":4,"repost":{"id":"1162556937","kind":"news","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1640178634,"share":"https://www.laohu8.com/m/news/1162556937?lang=zh_CN&edition=full","pubTime":"2021-12-22 21:10","market":"us","language":"en","title":"Cocrystal Pharma shares surged more than 9% in premarket trading<blockquote>Cocrystal Pharma股价在盘前交易中飙升超过9%</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1162556937","media":"Tiger Newspress","summary":"Cocrystal Pharma shares surged more than 9% in premarket trading.\nCocrystal Pharma, Inc. announces t","content":"<p>Cocrystal&nbsp;Pharma&nbsp;shares&nbsp;surged&nbsp;more&nbsp;than&nbsp;9%&nbsp;in&nbsp;premarket&nbsp;trading.</p><p><blockquote>Cocrystal Pharma股价在盘前交易中飙升超过9%。</blockquote></p><p> <img src=\"https://static.tigerbbs.com/870487e02f7b05efc76a12650bd3de5f\" tg-width=\"730\" tg-height=\"598\" referrerpolicy=\"no-referrer\">Cocrystal Pharma, Inc. announces that in vitro studies demonstrate its oral and intranasal/pulmonary SARS-CoV-2 main protease inhibitors exhibit antiviral potency against the Omicron variant. The Company earlier confirmed that its protease inhibitors demonstrated broad-spectrum antiviral activity against SARS-CoV-2 and all major previously identified variants including Delta, Alpha, Beta and Gamma. Cocrystal expects to initiate Phase 1 clinical studies with its COVID-19 intranasal/pulmonary protease inhibitor CDI-45205 and an oral COVID-19 protease inhibitor as rapidly as possible.</p><p><blockquote>Cocrystal Pharma，Inc.宣布，体外研究表明，其口服和鼻内/肺新型冠状病毒主要蛋白酶抑制剂对奥密克戎病毒变异体具有抗病毒效力。该公司早些时候证实，其蛋白酶抑制剂对新型冠状病毒病毒和所有先前确定的主要变异体（包括Delta、Alpha、Beta和Gamma）表现出广谱抗病毒活性。Cocrystal预计将尽快启动其COVID-19鼻内/肺蛋白酶抑制剂CDI-45205和口服COVID-19蛋白酶抑制剂的1期临床研究。</blockquote></p><p></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Cocrystal Pharma shares surged more than 9% in premarket trading<blockquote>Cocrystal Pharma股价在盘前交易中飙升超过9%</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCocrystal Pharma shares surged more than 9% in premarket trading<blockquote>Cocrystal Pharma股价在盘前交易中飙升超过9%</blockquote>\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time smaller\">2021-12-22 21:10</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<p>Cocrystal&nbsp;Pharma&nbsp;shares&nbsp;surged&nbsp;more&nbsp;than&nbsp;9%&nbsp;in&nbsp;premarket&nbsp;trading.</p><p><blockquote>Cocrystal Pharma股价在盘前交易中飙升超过9%。</blockquote></p><p> <img src=\"https://static.tigerbbs.com/870487e02f7b05efc76a12650bd3de5f\" tg-width=\"730\" tg-height=\"598\" referrerpolicy=\"no-referrer\">Cocrystal Pharma, Inc. announces that in vitro studies demonstrate its oral and intranasal/pulmonary SARS-CoV-2 main protease inhibitors exhibit antiviral potency against the Omicron variant. The Company earlier confirmed that its protease inhibitors demonstrated broad-spectrum antiviral activity against SARS-CoV-2 and all major previously identified variants including Delta, Alpha, Beta and Gamma. Cocrystal expects to initiate Phase 1 clinical studies with its COVID-19 intranasal/pulmonary protease inhibitor CDI-45205 and an oral COVID-19 protease inhibitor as rapidly as possible.</p><p><blockquote>Cocrystal Pharma，Inc.宣布，体外研究表明，其口服和鼻内/肺新型冠状病毒主要蛋白酶抑制剂对奥密克戎病毒变异体具有抗病毒效力。该公司早些时候证实，其蛋白酶抑制剂对新型冠状病毒病毒和所有先前确定的主要变异体（包括Delta、Alpha、Beta和Gamma）表现出广谱抗病毒活性。Cocrystal预计将尽快启动其COVID-19鼻内/肺蛋白酶抑制剂CDI-45205和口服COVID-19蛋白酶抑制剂的1期临床研究。</blockquote></p><p></p>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"COCP":"Cocrystal Pharma, Inc."},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1162556937","content_text":"Cocrystal Pharma shares surged more than 9% in premarket trading.\nCocrystal Pharma, Inc. announces that in vitro studies demonstrate its oral and intranasal/pulmonary SARS-CoV-2 main protease inhibitors exhibit antiviral potency against the Omicron variant. The Company earlier confirmed that its protease inhibitors demonstrated broad-spectrum antiviral activity against SARS-CoV-2 and all major previously identified variants including Delta, Alpha, Beta and Gamma. Cocrystal expects to initiate Phase 1 clinical studies with its COVID-19 intranasal/pulmonary protease inhibitor CDI-45205 and an oral COVID-19 protease inhibitor as rapidly as possible.","news_type":1,"symbols_score_info":{"COCP":0.9}},"isVote":1,"tweetType":1,"viewCount":2797,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":[],"verified":2,"subType":0,"readableState":1,"langContent":"CN","currentLanguage":"CN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":false,"andRepostAutoSelectedFlag":false,"upFlag":false,"length":36,"xxTargetLangEnum":"ZH_CN"},"commentList":[],"hasMoreComment":false,"orderType":2}